BioMarin Pharmaceutical Inc. Seen Luring $13 Billion Takeover Bid

BioMarin Pharmaceutical Inc. (BMRN) may draw bidders to the biggest biotechnology deal in three years after its most promising rare-disease drug came one step closer to U.S. regulatory approval this week.

An advisory committee to the Food and Drug Administration said this week that BioMarin’s Vimizim drug should be approved to treat the rare metabolic disease Morquio A syndrome. A favorable FDA ruling by the end of February would remove some risk for acquirers and may encourage them to pay a premium for the $9.8 billion company, Robert W. Baird & Co. said.

Help employers find you! Check out all the jobs and post your resume.